Results 211 to 220 of about 2,658,760 (317)

Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron‐laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab‐treated patients with at least
Kimberly H. Markowitz, Neha V. Safi, Iliana Pliska‐Bloch, Ulrike W. Kaunzner, Ha Luu, Mert Sisman, Yi Wang, Thanh D. Nguyen, Sandra Hurtado Rúa, Susan A. Gauthier   +9 more
wiley   +1 more source

Popular Financial Report of Harvard University FY 2024

European Journal of Volunteering and Community-Based Projects
Riccardo Corsi, Luca Accossato, Davide Ciniero, Federico Gribaldo   +3 more
doaj   +2 more sources

Assessment of Radiation Oncology Participation in Interdisciplinary Education at the American Society of Clinical Oncology Annual Meeting and Pathways to Expand Involvement. [PDF]

Adv Radiat Oncol
Sherwani ZK, Kumar R, Tabet A, Mattes MD.   +3 more
europepmc   +1 more source

The Annual Meeting

American Journal of Public Health and the Nations Health, 1958
openaire   +3 more sources

A Depolarizing Leak in Sodium Bicarbonate Cotransporter NBCe1 Causes Brain Edema

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives SLC4A4 encodes electrogenic sodium bicarbonate cotransporter NBCe1, prominently expressed in kidney and brain. Recessive loss‐of‐function variants in SLC4A4 cause proximal renal tubular acidosis, no brain edema. In the brain, NBCe1 is expressed by astrocytes, where it regulates pH and mediates astrocyte volume changes.
Quinty Bisseling, Mark D. Parker, Sven Kerst, Richard A. Pasternack, Jacob Tondreau, Marjolein Breur, Gemma M. van Rooijen‐van Leeuwen, Davide Tonduti, Ettore Salsano, Alejandra Darling, Joanna A. E. van Wijk, Susanna Törnroth‐Horsefield, Marianna Bugiani, Petra J. W. Pouwels, Quinten Waisfisz, Marjo S. van der Knaap, Rogier Min   +16 more
wiley   +1 more source

Cell Therapy '98: An Introduction

Cell Transplantation, 1999
Morito Monden
doaj   +1 more source

Monthly out-of-pocket caps substantially increase actuarial value for high-deductible health plans: a simulation study. [PDF]

Health Aff Sch
Anderson DM, Shafer PR.
europepmc   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Annals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
wiley   +1 more source

Cell Therapy ‘99: Introduction

Cell Transplantation, 2000
Hiroshi Amemiya
doaj   +1 more source

Secular trends in HbA1c levels among children and adolescents with type 1 diabetes. [PDF]

Front Endocrinol (Lausanne)
Chou J, Lin CH, Lin SK, Lee YJ, Huang CY, Kao YE, Yu JC, Ting WH.   +7 more
europepmc   +1 more source